UNSPSC 51384508: Flurbiprofen

This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor with the molecular formula C15H13FO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5GRO578KLP, chemically known as 4-biphenylacetic acid, 2-fluoro-alpha-methyl- but generally known as flurbiprofen, which bears US NIH Compound Identifier 3394. European Medicines Agency schedules Flurbiprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07745MIG.

UNSPSC 51384508 Flurbiprofen, a Commodity code, nominally covers anti-inflammatory pharmaceutical products, yet the single recent state-local opportunity posted under this code shows a substantial mismatch: Seminole County, Florida issued IFB 60459723LAS to procure naloxone and drug deactivation systems — opioid-reversal and harm-reduction supplies entirely outside the flurbiprofen category. The source provides no evidence of state or local government bodies actually soliciting flurbiprofen itself under this code in the recent period. This code shows little relevant recent activity for pharmaceutical procurement professionals targeting state and local buyers.

Seminole County's naloxone and deactivation-systems procurement (IFB posted June 30, 2026, response due July 26, 2023) called for 1,900 units of naloxone and 800 drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract included a two-year initial term with one-year renewal option, required E-Verify compliance and drug-free workplace certification, and was potentially FEMA-funded. This single opportunity does not establish a pattern of state or local flurbiprofen purchasing, nor does it clarify whether the code assignment reflects an actual buy stream or a data-entry error in the jurisdiction's classification system.